76
Views
5
CrossRef citations to date
0
Altmetric
Research Article

Sperm-associated antigen 9 overexpression correlates with poor prognosis and insensitive to Taxol treatment in breast cancer

, , &
Pages 62-67 | Received 09 Jan 2015, Accepted 01 Nov 2015, Published online: 03 Dec 2015

References

  • Garg M, Chaurasiya D, Rana R, et al. (2007). Sperm-associated antigen 9, a novel cancer testis antigen, is a potential target for immunotherapy in epithelial ovarian cancer. Clin Cancer Res 13:1421–8
  • Garg M, Kanojia D, Khosla A, et al. (2008). Sperm-associated antigen 9 is associated with tumor growth, migration, and invasion in renal cell carcinoma. Cancer Res 68:8240–8
  • Garg M, Kanojia D, Salhan S, et al. (2009a). Sperm-associated antigen 9 is a biomarker for early cervical carcinoma. Cancer 115:2671–83
  • Garg M, Kanojia D, Suri S, et al. (2009b). Sperm-associated antigen 9: a novel diagnostic marker for thyroid cancer. J Clin Endocrinol Metab 94:4613–18
  • Garg M, Kanojia D, Suri S, et al. (2009c). Small interfering RNA-mediated down-regulation of SPAG9 inhibits cervical tumor growth. Cancer 115:5688–99
  • Jagadish N, Rana R, Selvi R, et al. (2005). Characterization of a novel human sperm-associated antigen 9 (SPAG9) having structural homology with c-Jun N-terminal kinase-interacting protein. Biochem J 389:73–82
  • Kanojia D, Garg M, Gupta S, et al. (2009). Sperm-associated antigen 9, a novel biomarker for early detection of breast cancer. Cancer Epidemiol Biomarkers Prev 18:630–9
  • Kanojia D, Garg M, Gupta S, et al. (2011). Sperm-associated antigen 9 is a novel biomarker for colorectal cancer and is involved in tumor growth and tumorigenicity. Am J Pathol 178:1009–20
  • Kanojia D, Garg M, Saini S, et al. (2010). Sperm associated antigen 9 expression and humoral response in chronic myeloid leukemia. Leuk Res 34:858–63
  • Kanojia D, Garg M, Saini S, et al. (2013). Sperm associated antigen 9 plays an important role in bladder transitional cell carcinoma. PLoS One 8:e81348
  • Li H, Peng Y, Niu H, et al. (2014). SPAG9 is overexpressed in human prostate cancer and promotes cancer cell proliferation. Tumour Biol 35:6949–54
  • Olopade OI, Grushko TA, Nanda R, et al. (2008). Advances in breast cancer: pathways to personalized medicine. Clin Cancer Res 14:7988–99
  • Park S, Lim Y, Lee D, et al. (2003). Identification and characterization of a novel cancer/testis antigen gene CAGE-1. Biochim Biophys Acta 1625:173–82
  • Rana R, Jagadish N, Garg M, et al. (2006). Small interference RNA-mediated knockdown of sperm associated antigen 9 having structural homology with c-Jun N-terminal kinase-interacting protein. Biochem Biophys Res Commun 340:158–64
  • Sarcevic B, Spagnoli GC, Terracciano L, et al. (2003). Expression of cancer/testis tumor associated antigens in cervical squamous cell carcinoma. Oncology 64:443–9
  • Seleit I, Bakry OA, Samaka RM, et al. (2014). Immunohistochemical expression of sperm-associated antigen 9 in nonmelanoma skin cancer. Am J Dermatopathol 37:38–45
  • Siegel RL, Miller KD, Jemal A. (2015). Cancer statistics, 2015. CA Cancer J Clin 65:5–29
  • Singson A, Zannoni S, Kadandale P. (2001). Molecules that function in the steps of fertilization. Cytokine Growth Factor Rev 12:299–304
  • Sinha A, Agarwal S, Parashar D, et al. (2013). Down regulation of SPAG9 reduces growth and invasive potential of triple-negative breast cancer cells: possible implications in targeted therapy. J Exp Clin Cancer Res 19:69
  • Suri A, Saini S, Sinha A, et al. (2012). Cancer testis antigens: a new paradigm for cancer therapy. Oncoimmunology 1:1194–6
  • Wang Y, Dong Q, Miao Y, et al. (2013). Clinical significance and biological roles of SPAG9 overexpression in non-small cell lung cancer. Lung Cancer 81:266–72
  • Xie C, Fu L, Liu N, et al. (2014). Overexpression of SPAG9 correlates with poor prognosis and tumor progression in hepatocellular carcinoma. Tumour Biol 35:7685–91
  • Yi F, Ni W, Liu W, et al. (2013). SPAG9 is overexpressed in human astrocytoma and promotes cell proliferation and invasion. Tumour Biol 34:2849–55

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.